Nutritional Growth Solutions (ASX:NGS) has announced the commencement of a clinical trial to evaluate the effects of their innovative sports supplement on physical activity performance of young soccer players.
The trial will be a randomised, double-blind, placebo-controlled pilot that will recruit up to 50 healthy soccer players ages 8-15 years old.
The clinical trial comprises of an 8-week treatment period followed by an 8-week open-label period, with initial results expected in Q3 2023.
The NGS innovative nutritional supplement contains high quality whey proteins, additional specific amino acids, creatine monohydrate, carbohydrates, fats, and micronutrients (including calcium, iron, zinc, magnesium, vitamin A, vitamin C, vitamin D, vitamin E and vitamin B complex).
The company is investing up to $100k in this clinical trial with the aim of offering active children a safe and effective nutritional supplement.
Results of the trial are expected in Q3 2023.
Following the announcement, shares of Nutritional Growth Solutions (ASX:NGS) were unchanged at $0.057.